array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(13) "Pharming B.V."
["slug"]=>
string(20) "00474-nl-pharming-bv"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/6f06b060-b806-43f2-addd-a605083bf776"
["description"]=>
string(987) "Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates."
["address_street"]=>
string(12) "Darwinweg 24"
["address_place"]=>
string(6) "Leiden"
["address_region"]=>
NULL
["founding_date"]=>
NULL
["website_domain"]=>
string(12) "pharming.com"
["website_url"]=>
string(24) "https://www.pharming.com"
["industry_codes"]=>
array(1) {
[0]=>
string(75) "Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified"
}
["employee_count"]=>
NULL
["article_count"]=>
int(54)
}
["articles"]=>
array(3) {
[0]=>
array(7) {
["title_en"]=>
string(84) "Pharming's share price rises by more than 9% thanks to higher than expected turnover"
["snippet_en"]=>
string(145) "Sales growth of 10% from medicine Ruconest is higher than the company expected. Investors react enthusiastically to the message and set course..."
["url"]=>
string(111) "https://fd.nl/financiele-markten/3693272/1502485/koers-pharming-stijgt-ruim-9-dankzij-hoger-dan-verwachte-omzet"
["image_url"]=>
NULL
["source"]=>
string(5) "fd.nl"
["publication_date"]=>
string(10) "2024-01-08"
["categories"]=>
array(5) {
[0]=>
string(12) "Stock Market"
[1]=>
string(24) "Quarterly/Annual Figures"
[2]=>
string(15) "Market Movement"
[3]=>
string(9) "Investors"
[4]=>
string(25) "Business Model Resilience"
}
}
[1]=>
array(7) {
["title_en"]=>
string(72) "European stock markets rose slightly after a week of interest rate fears"
["snippet_en"]=>
string(184) "AMSTERDAM (ANP) - The European stock markets showed some recovery on Friday after the significant price losses earlier this week. The fear of higher interest rates, which the markets d"
["url"]=>
string(85) "https://www.zeelandnet.nl/nieuws/europese-beurzen-licht-omhoog-na-week-van-rentevrees"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/15fb18ac-5c61-4a8a-8f27-f1d9fce54f25"
["source"]=>
string(13) "zeelandnet.nl"
["publication_date"]=>
string(10) "2021-05-14"
["categories"]=>
array(3) {
[0]=>
string(12) "Stock Market"
[1]=>
string(15) "Market Movement"
[2]=>
string(19) "Economic Conditions"
}
}
[2]=>
array(7) {
["title_en"]=>
string(27) "'AEX continues its decline'"
["snippet_en"]=>
string(252) "The stock exchange in Amsterdam will probably open with a loss on Thursday. The other stock exchanges in Europe also seem to start lower after the heavy price losses in Asia and on Wall Street. Investors are once again getting a good amount of business"
["url"]=>
string(73) "https://www.telegraaf.nl/financieel/2724384/aex-zet-neergang-stevig-voort"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/d684a4f8-4f2e-4f99-8b86-196d5b2e5a08"
["source"]=>
string(12) "telegraaf.nl"
["publication_date"]=>
string(10) "2018-10-24"
["categories"]=>
array(3) {
[0]=>
string(12) "Stock Market"
[1]=>
string(15) "Market Movement"
[2]=>
string(9) "Investors"
}
}
}
["category_annotations"]=>
array(28) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(12)
}
[1]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(8)
}
[2]=>
array(2) {
["name"]=>
string(10) "Insolvency"
["count"]=>
int(4)
}
[3]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(4)
}
[4]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(3)
}
[5]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(3)
}
[6]=>
array(2) {
["name"]=>
string(9) "Investors"
["count"]=>
int(2)
}
[7]=>
array(2) {
["name"]=>
string(21) "Financial Performance"
["count"]=>
int(2)
}
[8]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(2)
}
[9]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(1)
}
[10]=>
array(2) {
["name"]=>
string(10) "Executives"
["count"]=>
int(1)
}
[11]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(1)
}
[12]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(1)
}
[13]=>
array(2) {
["name"]=>
string(24) "Government Interventions"
["count"]=>
int(1)
}
[14]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(1)
}
[15]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(1)
}
[16]=>
array(2) {
["name"]=>
string(21) "Shareholders Feedback"
["count"]=>
int(1)
}
[17]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(1)
}
[18]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(1)
}
[19]=>
array(2) {
["name"]=>
string(9) "Valuation"
["count"]=>
int(1)
}
[20]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(1)
}
[21]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(1)
}
[22]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(1)
}
[23]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(1)
}
[24]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(1)
}
[25]=>
array(2) {
["name"]=>
string(5) "Debts"
["count"]=>
int(1)
}
[26]=>
array(2) {
["name"]=>
string(19) "Economic Conditions"
["count"]=>
int(1)
}
[27]=>
array(2) {
["name"]=>
string(7) "Economy"
["count"]=>
int(1)
}
}
}
00474-nl-pharming-bv
Pharming B.V.
Location
Founded
Website
https://www.pharming.com
Articles
54 Articles
Category
Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified
Description
Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates.
AMSTERDAM (ANP) - The European stock markets showed some recovery on Friday after the significant price losses earlier this week. The fear of higher interest rates, which the markets d
The stock exchange in Amsterdam will probably open with a loss on Thursday. The other stock exchanges in Europe also seem to start lower after the heavy price losses in Asia and on Wall Street. Investors are once again getting a good amount of business
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
